purpos
studi
probe
antirhinoviru
rv
mechan
action
mdl
evalu
compound
effect
rv
rna
synthesi
uncoat
neutral
redsensit
rv
plasma
membran
penetr
rv
stabil
rv
heat
low
ph
inactiv
studi
mdl
rv
mutant
indic
mdl
bind
directli
rv
capsid
subsequ
inhibit
acidmedi
virion
uncoat
ano
pyridin
potent
antirhinoviru
compound
median
plaqu
reduct
ixgml
serotyp
evalu
kenni
et
al
compound
also
activ
human
simian
bovin
rotavirus
cpe
txgml
possess
variabl
enteroviru
paramyxoviru
activ
mdl
activ
cpe
lgml
orthomyxovirus
human
coronaviru
adenovirus
herp
simplex
viru
addit
mdl
measur
effect
macromolecular
synthesi
clone
effici
hela
cell
compound
concentr
compound
mdl
fig
fig
synthes
publish
method
bargar
et
al
hopkin
rhinovirus
rv
obtain
bd
korant
ei
dupont
denemour
co
inc
wilmington
de
experiment
stock
prepar
hela
cell
rhinoviru
atcc
asgp
antisera
atcc
asgp
correspond
preimmun
control
sera
atcc
pigp
atcc
pigp
purchas
american
type
cultur
collect
atcc
rockvil
md
hela
cell
gibco
grand
island
ny
grown
maintain
corn
cm
tissu
cultur
flask
scientif
product
mcgaw
park
il
use
minim
essenti
medium
earl
salt
emem
gibco
supplement
igml
penicillin
g
ixgml
streptomycin
sulfat
igml
neomycin
sulfat
psn
gibco
heatinactiv
fetal
bovin
serum
hifb
jr
scientif
inc
woodland
ca
use
cell
growth
growth
medium
concentr
reduc
cell
mainten
mainten
medium
viru
assay
hela
cell
seed
flatbottom
plate
falcon
concentr
cellsml
ml
growth
medium
per
well
plate
costar
cambridg
concentr
cellsml
ml
growth
medium
per
well
plate
costar
concentr
cellsml
ml
growth
medium
plate
incub
humidifi
co
air
incub
day
allow
monolay
format
viru
plaqu
cytopath
effect
endpoint
assay
perform
hela
cell
previous
describ
kenni
et
al
torney
et
al
hela
cell
microtit
plate
treat
g
mdl
ml
mainten
medium
h
viru
adsorpt
cultur
compoundfre
mainten
medium
also
includ
use
compound
control
studi
postinfect
compound
effect
concentr
mdl
employ
excess
rv
viru
challeng
medium
remov
monolay
inocul
ml
rv
moi
mainten
medium
contain
ixg
mdl
continu
pretreat
seri
initi
postinfect
treatment
seri
compoundfre
mainten
medium
viru
control
adsorpt
period
h
excess
inoculum
remov
monolay
wash
compoundfre
mainten
medium
cultur
refe
ml
mainten
medium
contain
g
mdl
compoundfre
mainten
medium
viru
control
manner
cultur
treat
mdl
h
rel
initi
rv
infect
variabl
test
quadrupl
incub
cultur
frozen
measur
viru
yield
sampl
cultur
thaw
cell
scrape
cultur
fluid
sampl
replic
pool
addit
freezethaw
cycl
sampl
clarifi
centrifug
cold
x
g
min
result
supern
assay
plaqu
reduct
method
effect
mdl
rv
actinomycin
dresist
rna
synthesi
measur
indirectli
determin
incorpor
uridin
trichloroacet
acid
tca
insolubl
cell
fraction
virion
uncoat
monitor
use
neutral
red
photosensit
rv
detail
descript
techniqu
publish
previous
kenni
et
al
kuchler
torney
et
al
effect
mdl
rv
penetr
examin
method
egger
et
al
briefli
growth
medium
aspir
hela
cell
cultur
plate
monolay
wash
ml
hank
balanc
salt
solut
hbss
three
cultur
use
variabl
wash
ml
pfu
viru
ad
monolay
cultur
place
min
allow
viru
adsorpt
minim
viru
penetr
end
time
cultur
except
time
set
see
tabl
place
time
cultur
treat
ml
hbss
optimallydilut
rv
antiserum
ixgml
mdl
mixtur
antibodi
mdl
rain
room
temperatur
supernat
fluid
aspir
ml
agar
overlay
ad
procedur
repeat
viru
pretreat
cultur
incub
min
agar
overlay
ad
cultur
incub
day
allow
plaqu
develop
test
direct
virucid
activ
mdl
rv
incub
h
presenc
absenc
ixg
compoundml
surviv
viru
assay
cpe
endpoint
assay
determin
effect
mdl
rv
ph
stabil
txl
stock
viru
ml
ad
seri
test
tube
contain
ixl
acet
sodium
acet
buffer
solut
mix
give
final
ph
tisdal
selway
compound
ad
pxl
aliquot
mgml
stock
suspens
give
final
concentr
xgml
control
tube
ph
valu
receiv
ixl
mainten
medium
suffici
test
control
tube
prepar
sampl
could
assay
rain
incub
water
bath
design
time
interv
test
control
sampl
immedi
dilut
ice
cold
mainten
medium
dilut
prepar
cold
mainten
medium
cpe
endpoint
assay
determin
effect
mdl
rv
heat
stabil
ph
ixl
stock
viru
ml
ad
seri
test
tube
follow
addit
ixl
mgml
stock
compound
suspens
mainten
medium
test
suffici
tube
prepar
sampl
could
assay
min
incub
water
bath
design
time
interv
sampl
dilut
assay
infect
describ
prepar
start
materi
isol
area
cpe
surround
cell
remov
cm
hela
cell
flask
cultur
infect
rv
harvest
subject
freezethaw
cycl
pass
twice
hela
cell
obtain
larg
pool
parent
viru
design
rv
viru
ident
confirm
neutral
hyperimmun
refer
serum
isol
mdl
mutant
hela
cell
monolay
plate
pretreat
h
g
compound
ml
mainten
medium
monolay
challeng
rv
moi
compoundcontain
mainten
medium
monolay
overlay
ml
plaqu
medium
contain
g
mdl
cultur
incub
humidifi
incub
simultan
plaqu
titrat
challeng
viru
compoundfre
condit
also
perform
hour
isol
plaqu
pick
appropri
test
plate
monolay
stain
enumer
remain
plaqu
plaqu
count
use
determin
frequenc
mdl
resist
mutant
rv
popul
use
formula
fr
frequenc
resist
mutant
pcrx
plaqu
count
compoundtr
cultur
pcvc
plaqu
count
control
cultur
stock
resist
mutant
isol
sampl
plaqu
prepar
passag
noncompoundtr
hela
cell
ident
verifi
neutral
hyperimmun
rv
antiserum
preliminari
studi
fig
mdl
treatment
hela
cell
monolay
begun
variou
time
interv
high
moi
rv
challeng
show
compound
treatment
must
initi
time
viru
challeng
inhibit
viral
replic
data
infer
mdl
act
free
virion
earli
stage
viru
replic
cycl
b
expos
light
within
min
addit
viru
second
set
condit
c
expos
light
h
viru
challeng
third
set
condit
e
h
receiv
light
exposur
monolay
except
compound
condit
g
cell
condit
h
control
thoroughli
wash
h
viru
challeng
agar
overlay
medium
ad
plaqu
allow
develop
photosensit
rv
use
studi
shown
lack
plaqu
develop
cultur
light
exposur
begun
immedi
viru
addit
uncoat
could
occur
condit
b
amount
viru
uncoat
within
inocul
untreat
viru
control
cultur
condit
found
amount
gener
cultur
never
expos
light
condit
f
reduct
plaqu
develop
observ
unexpos
cultur
maintain
pg
mdl
throughout
durat
test
condit
g
experi
test
compound
could
remov
wash
shown
comparison
condit
e
f
residu
compound
effect
nonetheless
mdl
reduc
rv
plaqu
treat
cultur
expos
light
h
inocul
compar
untreat
cultur
condit
c
vs
result
show
effect
ig
mdl
rv
penetr
summar
tabl
evalu
time
data
show
pfu
input
viru
cellassoci
incub
step
condit
compound
appreci
effect
viru
stage
addit
cellassoci
viru
undergon
penetr
access
neutral
antibodi
condit
vs
b
increas
amount
viru
penetr
incub
continu
antibodi
ad
condit
vs
b
min
final
mdl
littl
effect
penetr
cellassoci
viru
condit
vs
c
b
vs
min
exposur
rv
ig
mdl
h
effect
viru
titer
replic
experi
preincub
titer
x
pfuml
postincub
titer
x
pfuml
obtain
tabl
show
mdl
stabil
compound
sensit
rv
inactiv
ph
rapid
inactiv
contrast
mdl
rv
mutant
stabil
propag
mdl
cpe
inhibit
txgml
rv
popul
presenc
variou
concentr
compound
show
studi
stabil
compound
resist
stock
resist
rv
isolatec
presenc
xg
mdl
pass
time
absenc
cc
pound
presenc
g
mdl
result
titer
passag
pfuml
pfuml
respect
viru
pro
gate
absenc
presenc
compound
assay
presel
compound
data
summar
tabl
show
rv
mdl
cross
resist
occur
mdl
pbenzoylphenoxypyridin
mdl
compound
mdl
one
activ
compound
seri
pyridin
synthes
antivir
compound
bargar
et
al
kenni
et
al
addit
mdl
display
littl
effect
hela
cell
macromolecular
synthesi
evalu
isotop
incorpor
clone
effici
kenni
et
al
present
studi
examin
antirhinoviru
mechan
action
mdl
analysi
growth
rv
compoundtr
untreat
hela
cell
suggest
mdl
act
directli
infect
virion
earli
stage
replic
cycl
subsequ
found
compound
block
viral
actinomycin
dresist
rna
synthesi
uncoat
neutral
red
photosensit
virion
addit
demonstr
mdl
directli
virucid
stabil
virion
inactiv
ph
comparison
antirhinoviru
compound
rp
alarcon
et
al
antipicornaviru
flavon
ro
ishitsuka
et
al
also
shown
act
earli
phase
viral
replic
cycl
antirhinoviru
tisdal
selway
antipicornaviru
compound
win
fox
et
al
mckinlay
otto
et
al
ro
ishitsuka
et
al
ninomiya
et
al
arildon
mcsharri
et
al
bind
directli
infect
virion
prevent
subsequ
phmediat
uncoat
viral
rna
recent
elucid
threedimension
structur
rv
capsid
rossmann
et
al
allow
studi
win
bind
molecular
level
smith
et
al
studi
indic
viru
uncoat
may
inhibit
compound
bind
virion
structur
protein
thu
prevent
collaps
hydrophob
pocket
block
flow
ion
viru
interior
uncoat
data
lack
mdl
compoundinduc
heat
low
ph
stabil
indic
direct
virion
bind
protein
stabil
earlier
studi
dimmock
shown
rv
inactiv
due
degrad
capsid
protein
compound
also
shown
stabil
rv
heat
low
ph
inactiv
tisdal
selway
cross
resist
mdl
mdl
inabl
mdl
stabil
compoundresist
mutant
shown
studi
cross
resist
demonstr
arildon
tisdal
selway
impli
common
virion
bind
site
four
compound
cross
resist
note
pbenzoylphenoxypyridin
mdl
compound
previous
shown
inhibit
uncoat
neutral
redsensit
coxsacki
kenni
et
al
compound
resist
rhinoviru
mutant
isol
ro
ahmad
et
al
ninomiya
et
al
tisdal
selway
win
fox
et
al
mdl
lack
suitabl
rv
anim
infect
model
make
difficult
compar
pathogenesi
compoundsuscept
parent
resist
mutant
rv
popul
reduc
virul
thymidin
kinaseneg
acyclovir
herp
simplex
mutant
note
mice
field
darbi
field
wildi
klein
et
al
present
studi
observ
mdl
resist
rv
mutant
grow
poorli
vitro
evidenc
delay
appear
reduct
plaqu
size
compar
compoundsensit
parent
popul
similar
chang
growth
characterist
recent
describ
ro
resist
rv
ahmad
et
al
summari
data
present
indic
mdl
probabl
act
stabil
rhinoviru
capsid
subsequ
degrad
uncoat
process
